Compare GTIM & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | BFRI |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 12.2M |
| IPO Year | 2013 | 2021 |
| Metric | GTIM | BFRI |
|---|---|---|
| Price | $1.28 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 40.2K | ★ 222.3K |
| Earning Date | 08-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $142,315,000.00 | $41,705,000.00 |
| Revenue This Year | N/A | $10.65 |
| Revenue Next Year | N/A | $15.88 |
| P/E Ratio | $6.10 | ★ N/A |
| Revenue Growth | 3.01 | ★ 11.75 |
| 52 Week Low | $1.10 | $0.57 |
| 52 Week High | $1.66 | $1.66 |
| Indicator | GTIM | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 32.31 | 41.99 |
| Support Level | $1.14 | $0.85 |
| Resistance Level | $1.34 | $0.97 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.27 | 51.74 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.